Overview

Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study, is to assess the effect of lanreotide Autogel 120mg on stool frequency in subjects with refractory diarrhea at day 28 (mean of last 7 days) compared to baseline.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ipsen
Treatments:
Angiopeptin
Lanreotide
Somatostatin